Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Amortizatization of Intangibles: 2015-2024

Historic Amortizatization of Intangibles for Rocket Pharmaceuticals (RCKT) over the last 8 years, with Dec 2024 value amounting to $8.1 million.

  • Rocket Pharmaceuticals' Amortizatization of Intangibles fell 9.19% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 27.82%. This contributed to the annual value of $8.1 million for FY2024, which is 24.16% down from last year.
  • Rocket Pharmaceuticals' Amortizatization of Intangibles amounted to $8.1 million in FY2024, which was down 24.16% from $10.7 million recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' Amortizatization of Intangibles ranged from a high of $10.7 million in FY2023 and a low of -$2.9 million during FY2021.
  • Its 3-year average for Amortizatization of Intangibles is $6.2 million, with a median of $8.1 million in 2024.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Amortizatization of Intangibles slumped by 205.58% in 2021, and later soared by 22,761.70% in 2023.
  • Yearly analysis of 5 years shows Rocket Pharmaceuticals' Amortizatization of Intangibles stood at $2.8 million in 2020, then plummeted by 205.58% to -$2.9 million in 2021, then soared by 98.39% to -$47,000 in 2022, then soared by 22,761.70% to $10.7 million in 2023, then fell by 24.16% to $8.1 million in 2024.